A Study to Analyze Predictive Pharmacogenomics in Fibromyalgia

Overview

About this study

The purpose of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of patients with fibromyalgia in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patient age 18 or above.
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.

Exclusion Criteria: 

  • Chronic fatigue syndrome in the absence of fibromyalgia.
  • Ative suicidal ideation.
  • Bipolar disorder.
  • Schizophrenia and schizoaffective disorder.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Dennis Bierle, M.D.

Closed for enrollment

Contact information:

Arya Mohabbat M.D.

(507)284-9039

Mohabbat.Arya@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20463728

Mayo Clinic Footer